| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9037 | Belantamab mafodontin-blmf | Blenrep | 0.5mg | Immunotherapy | Drug Antibody Conjugate | BCMA | No | 2020 | Apr 1, 2021 | Mar 26, 2025 | No Longer Used | |
| C9069 | Belantamab mafodotin-blmf | Blenrep | 0.5mg | Immunotherapy | Drug Antibody Conjugate | BCMA | No | 2020 | Jan 1, 2021 | No Longer Used | ||
| J0641 | Levoleucovorin | Fusilev, Levoleucovorin | 0.5 mg | Ancillary Therapy | Chemoprotective | Antidote | No | 2008 | Oct 1, 2019 | In Use | ||
| J9263 | Oxaliplatin | Eloxatin | 0.5 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2002 | Jan 1, 2004 | In Use | ||
| NA | Anastrozole | Arimidex | 0.5 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | In Use | ||||
| NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
| J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
| J9120 | Dactinomycin | Cosmegen | 0.5 mg | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | No | 1964 | Jan 1, 1984 | In Use | ||
| NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.3 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
| NA | Naldemedine | Symproic | 0.2mg | Ancillary Therapy | Opioid Antagonist | Yes | 2018 | In Use | ||||
| NA | Talazoparib | Talzenna | 0.25mg, 1mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2018 | In Use | |||
| J2277 | Motixafortide | Motixafortide | 0.25mg | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | No | 2023 | Apr 17, 2024 | In Use | ||
| J9177 | Enfortumab vedotin-ejfv | Padcev | 0.25mg | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | No | 2019 | Jul 1, 2020 | In Use | ||
| C9163 | Talquetamab | Talvey | 0.25mg | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
| J0896 | Luspatercept | Reblozyl | 0.25mg | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 2019 | Jul 1, 2020 | In Use | |||
| J8540 | Dexamethasone Oral | Baycadron, ZoDex, Decadron | 0.25 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1983 | Jan 1, 2006 | In Use | ||
| J8561 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2012 | Dec 31, 2012 | No Longer Used | |
| J7527 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2013 | In Use | ||
| J8705 | Topotecan | Hycamtin | 0.25 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | Yes | 1996 | Jan 1, 2009 | In Use | ||
| Q2024 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Oct 1, 2009 | Dec 31, 2009 | No Longer Used | |
| C9257 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan 1, 2010 | In Use | ||
| J9223 | Lurbinectedin | Zepzelca | 0.1mg | Chemotherapy | Alkylating Agent | Adduct Forming Agent | No | 2020 | Jan 1, 2021 | In Use | ||
| J9352 | Trabectedin | Yondelis | 0.1mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jan 1, 2017 | In Use | ||
| J9318 | Romidepsin, non-lyophilized | Romidepsin | 0.1mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2020 | Sep 27, 2021 | In Use | ||
| J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home